5项改良衰弱指数预测脊柱立体定向放疗后局部控制与总生存
该单中心前瞻性数据库研究纳入2007-2024年接受脊柱SBRT的205例脊柱转移瘤及原发骨肿瘤患者,用mFI-5分为衰弱前期(mFI-5 0-1,180个病灶)和衰弱组(mFI-5 2-5,131个病灶)。衰弱组局部控制和总生存均较差,多因素分析显示衰弱与较差局部控制及总生存独立相关。
要点
- mFI-5评估的衰弱与脊柱SBRT后较差局部控制独立相关(HR 2.70)。
- 衰弱亦与较差总生存独立相关(HR 1.72)。
- 疼痛反应、放射性毒性及椎体压缩骨折在两组间无差异。
核心结论
- mFI-5评估的衰弱与脊柱SBRT后较差的局部控制和总生存相关。
研究设计与样本
- 单中心前瞻性维护数据库分析,纳入2007至2024年接受SBRT的脊柱转移瘤和原发骨肿瘤连续患者。
- 205例患者按mFI-5分为衰弱前期(0-1分,180个病灶)和衰弱组(2-5分,131个病灶)。
主要发现
- 衰弱组6个月、1年、2年、3年局部控制率分别为87%、77%、70%、65%,低于衰弱前期组的96%、92%、89%、87%(P < 0.001)。
- 竞争风险模型显示衰弱组局部失败累积发生率分别为13%、20%、24%、25%,高于衰弱前期组的4%、7%、9%、10%(P < 0.001)。
- 衰弱组6个月、1年、2年、3年总生存率分别为70%、51%、34%、30%,低于衰弱前期组的90%、72%、57%、47%(P < 0.001)。
- 1、3、6、12个月疼痛完全或部分缓解率(P = 0.345、P = 0.940、P = 0.766、P = 0.108)、放射性毒性(P = 0.832)及椎体压缩骨折(P = 0.504)两组无差异。
- 多因素分析中,衰弱(mFI-5 2-5;P < 0.001,HR 2.70,95% CI 1.54-4.76)和SINS > 6(P = 0.005,HR 4.12,95% CI 1.55-11.0)与较差局部控制相关;衰弱(P = 0.001,HR 1.72,95% CI 1.24-2.38)、既往常规外照射(P = 0.033,HR 1.49,95% CI 1.03-2.14)和ESCC评分 > 0(P = 0.039,HR 1.41,95% CI 1.02-1.96)与较差总生存相关。
临床怎么用
- 脊柱SBRT前可采用mFI-5评估衰弱状态,辅助预测局部控制和生存预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Frailty is an established prognostic factor in neurosurgical and oncologic populations. The association between frailty and outcomes following spine stereotactic body radiation therapy (SBRT) has not been previously evaluated using a validated clinical index. METHODS: A prospectively maintained, single-institution database of consecutive patients with spinal metastases and primary bone tumors treated with SBRT from 2007 to 2024 was analyzed. Frailty was assessed at the time of treatment using the 5-factor modified frailty index (mFI-5), with 205 patients stratified into pre-frail (mFI-5 0–1, 180 lesions) or frail (mFI-5 2–5, 131 lesions) cohorts. RESULTS: Kaplan-Meier estimates of 6-month, 1-year, 2-year, and 3-year local control (LC) were inferior in the frail cohort compared to the pre-frail cohort (87%, 77%, 70%, and 65% vs. 96%, 92%, 89%, and 87%; P < 0.001). Cumulative incidence competing risk estimates accounting for death showed higher local failure in the frail cohort (13%, 20%, 24%, and 25% vs. 4%, 7%, 9%, and 10%; P < 0.001). Kaplan-Meier estimates of 6-month, 1-year, 2-year, and 3-year overall survival (OS) were inferior in the frail cohort (70%, 51%, 34%, and 30% vs. 90%, 72%, 57%, and 47%; P < 0.001). Complete or partial pain response at 1, 3, 6, or 12 months (P = 0.345, P = 0.940, P = 0.766, P = 0.108), radiation toxicity (P = 0.832), and vertebral compression fractures (P = 0.504) following treatment did not differ between cohorts. On multivariable analysis, frailty (mFI-5 2–5; P < 0.001, HR: 2.70, 95% CI: 1.54–4.76) and Spinal Instability Neoplastic Score > 6 (P = 0.005, HR: 4.12, 95% CI: 1.55-11.0) were associated with inferior LC. Frailty (P = 0.001, HR: 1.72, 95% CI: 1.24–2.38), prior conventional external beam radiation therapy (P = 0.033, HR: 1.49, 95% CI: 1.03–2.14), and Epidural Spinal Cord Compression score > 0 (P = 0.039, HR: 1.41, 95% CI: 1.02–1.96) were associated with inferior OS. CONCLUSION: Frailty as measured by the mFI-5 was associated with inferior LC and OS following spine SBRT.
引用
- Adida S, Taori S, Rabon W, et al. The 5-factor modified frailty index predicts local control and overall survival following spine stereotactic body radiation therapy. J Neurooncol. 2026. PMID: 41762350. doi:10.1007/s11060-026-05488-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。